Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Impact Biomedicines Inc.

Division of Celgene Corp.
www.impactbiomedicines.com

Latest From Impact Biomedicines Inc.

Inrebic Approval Is A Boost For Myelofibrosis And Celgene's Buyer Bristol

Investors in Impact Biosciences, which sold the selective JAK2 inhibitor to Celgene for $1.1bn up front, could double their money with milestone fees based on fedratinib's approval.

Approvals Cancer

Keeping Track: Accelerated Approval For Tecentriq And A Burst Of Filings And Submissions

The latest drug development news and highlights from our US FDA Performance Tracker. 
Drug Review Regulation

Celgene Gives Reassurances That Key Products And Programs Remain On Track

Celgene's quarterly earnings call was all about reassuring investors that its products and pipeline will deliver the full value of the company's acquisition by Bristol-Myers after the deal closes in the third quarter.

Sales & Earnings Research and Development Strategies

Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?

Bristol's surprising purchase diversifies its portfolio beyond Opdivo, while stopping Celgene's ongoing stock price declines after several setbacks. While Bristol execs downplayed the mid-term risk of generics for Celgene's blockbuster Revlimid, they highlighted near- and long-term growth drivers.

M & A Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Celgene Corp.
  • Senior Management
  • John Hood, PhD, CEO
    Raghu Saripalli, CFO
    Catriona Jamieson, MD, PhD, Interim CMO
    Charles McDermott, Pres. & CBO
  • Contact Info
  • Impact Biomedicines Inc.
    Phone: (858) 221-0950
    12526 High Bluff Dr.
    Ste. 260
    San Diego, CA 92130
    USA
UsernamePublicRestriction

Register